Clovis Oncology, Inc. (CLVS)
(Delayed Data from NSDQ)
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
What's in Store for Jounce (JNCE) This Earnings Season?
by Zacks Equity Research
Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.
What's in Store for Aimmune (AIMT) This Earnings Season?
by Zacks Equity Research
Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.
Is a Beat in the Cards for Clovis' (CLVS) Earnings in Q4?
by Zacks Equity Research
Clovis' (CLVS) sole marketed drug, Rubraca, is likely to have driven revenues in the fourth quarter.
Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
What's in Store for Corcept (CORT) This Earnings Season?
by Zacks Equity Research
During Corcept's (CORT) Q4 earnings call, investor focus will be on the sales uptake of its Cushing's syndrome drug Korlym and other pipeline updates.
Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on merger with Upjohn, when Mylan (MYL) reports Q4 results.
5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Is a Beat in the Cards for Humana's (HUM) Earnings in Q4?
by Zacks Equity Research
Humana's (HUM) fourth-quarter results are likely to reflect lower membership, partly offset by higher revenues.
Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study
by Zacks Equity Research
Acceleron (XLRN) stock surges as sotatercept meets primary and secondary endpoints in a phase II study in patients with pulmonary arterial hypertension.
Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon
by Zacks Equity Research
A low-key week for the biotech sector with a few pipeline and regulatory updates.
Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review
by Zacks Equity Research
Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.
Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020
by Benjamin Rains
Here are 5 of the 36 highly-ranked stocks trading under $10 a share that made it through today's screen...
Implied Volatility Surging for Clovis (CLVS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Clovis (CLVS) stock based on the movements in the options market lately.
FDA Accepts Immunomedics' BLA Refiling for Breast Cancer Drug
by Zacks Equity Research
The FDA accepts Immunomedics' (IMMU) BLA resubmission for sacituzumab govitecan to treat patients with metastatic triple-negative breast cancer, having received at least two prior therapies.
Corporate News for Dec 18, 2019
by Zacks Equity Research
Companies In The News Are: TGE, WOR, UL, CLVS
Implied Volatility Surging for Clovis (CLVS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Clovis (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) Up 122.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunomedics Resubmits Application for Breast Cancer Drug
by Zacks Equity Research
Immunomedics (IMMU) resubmits BLA to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer, who have received at least two prior therapies.
Biotech Tops in November: Best ETFs & Stocks
by Sweta Killa
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
Clovis Oncology, Inc. (CLVS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Clovis Oncology, Inc. (CLVS).
Clovis (CLVS) Looks Good: Stock Adds 6.3% in Session
by Zacks Equity Research
Clovis (CLVS) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Clovis (CLVS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Clovis (CLVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks
by Sanghamitra Saha
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up
by Zacks Equity Research
Clovis (CLVS) reports encouraging third-quarter 2019 results. The company tightens guidance for product sales in 2019.